BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a ...

Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target Don't Miss our Black Friday Offers: Discover the latest stocks recommended by top Wall Street analysts, all in ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for ...

NASDAQ:VYNE opened at $3.16 on Friday. The firm has a market capitalization of $46.61 million, a PE ratio of -1.22 and a beta of 1.32. The stock’s fifty day moving average is $2.17 and its 200 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Net loss: US$12.2m (loss widened by 100% from 3Q 2023). US$0.28 loss per share. Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 23%. Looking ahead, ...

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development ...

The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025. The Phase 2b trial (NCT06493578) is a randomized ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025 Reported positive first-in-human Phase 1a SAD data ...